Clinical Trial · NCT03039413

Copper Cu-64 TP3805 PET/CT in Imaging Patients With Urothelial Cancer Undergoing Surgery or Biopsy

Overview

This pilot clinical trial studies how well copper Cu-64 TP3805 positron emission tomography (PET)/computed tomography (CT) works in imaging patients with urothelial cancer undergoing surgery or biopsy. Radioactive tracers, such as copper Cu-64 TP3805, may bind to tumor cells. PET/CT imaging performed with copper Cu-64 TP3805 may be a better way to detect urothelial cancer.

Sponsor

Unknown Organization

Phase

Early Phase 1

Contacts

Madhukar Thakur, PhD (PRINCIPAL_INVESTIGATOR)

ClinicalTrials.gov

NCT03039413

Drug / Compound

TP3805

Isotope(s):

Target(s):

Vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptor 1 (VPAC1)

Ligand Class: Peptides

Eligibility

Inclusion

Must have diagnosis of urothelial cancer
Scheduled for extirpative surgery or biopsy of suspected metastatic lesion

Exclusion

Must not have had an injection of a radioisotope 24 hours prior to exam